ZYXEL-COMMUNICATIONS
26.5.2020 08:02:04 CEST | Business Wire | Press release
Zyxel Communications announced its 5G Fixed Wireless Access (FWA) product portfolio is available for service providers and mass production will begin as soon as Q2 2020. To accelerate your business with Zyxel 5G NR FWA, click here .
Today’s subscribers expect robust bandwidth and low latency. Some households, however, are limited in terms of reliable broadband connections. The Zyxel FWA portfolio helps service providers leverage 5G NR technology to deliver high-capacity, premium broadband services, high-speed connectivity, enhanced network security, and deployment flexibility.
With outdoor, indoor, and portable options, Zyxel offers a wide range of products with its 5G NR FWA portfolio, including:
· 5G NR Outdoor Router (NR7101)
· 5G NR Indoor Router (NR5101)
· 5G NR Portable Router (NR2101)
Together, these solutions ensure connectivity everywhere. Combining the latest in WiFi 6 technology, Zyxel’s 5G NR solution portfolio creates a superior, ultra-high speed and zero-dead-zone WiFi experience for service providers and their subscribers.
Zyxel’s 5G NR FWA solutions are also equipped with a simple and intuitive mobile app that enables subscribers to easily install and connect devices to their network. The app significantly reduces installation time and the need for costly professional installations. Subscribers can also leverage the mobile app to reinforce CPE placement and achieve the best possible 5G connection.
“5G NR offers the opportunity for service providers to create a bigger pipeline, faster data streaming and ultra-low latency, all of which subscribers want and need, especially during a time where more people are logging on from home than ever before,” said Karsten Gewecke, Senior VP, Head of EMEA Regional BU at Zyxel Communications. “The launch of Zyxel’s 5G Fixed Wireless Access portfolio demonstrates our commitment to helping service providers generate new business opportunities and the best subscriber experience possible.”
Availability
NR7101, NR5101, and NR2101 will be available for service providers in EMEA region as soon as Q2 2020. Service providers can contact their local Zyxel representatives for availability. For more product information, please visit the Zyxel global website .
About Zyxel Communications
Zyxel delivers technological innovations and has connected the world to the Internet for more than 30 years. Whether it’s a matter of establishing access through fixed or mobile broadband solutions, at Zyxel we offer a comprehensive and flexible portfolio of products that’s right for Service Providers and their subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200525005314/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom